This study will evaluate the safety, MTD and/or RP2D, PK, and clinical activity of the
combination of adagrasib with nab-sirolimus in patients with advanced solid tumors/NSCLC
with a KRAS G12C mutation.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT05840510.
This study will evaluate the safety and tolerability and clinical activity of adagrasib
in combination with nab-sirolimus in patients with advanced solid tumors harboring a KRAS
G12C mutation.
The Phase 1 portion will enroll advanced solid tumors to establish the maximum tolerated
dose (MTD) and/or to identify recommended Phase 2 combinatorial doses. The Phase 2
portion will enroll patients with NSCLC to further evaluate the safety/tolerability and
clinical activity.
Adagrasib is an orally available small molecule inhibitor of KRAS G12C. nab-Sirolimus is
a nanoparticle albumin-bound (nab) form of sirolimus, and sirolimus is an inhibitor of
mechanistic target of rapamycin kinase (mTOR, previously known as mammalian target of
rapamycin).
Lead OrganizationMirati Therapeutics
